285 related articles for article (PubMed ID: 26252465)
1. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.
Zhang W; Lu X; Cui P; Piao C; Xiao M; Liu X; Wang Y; Wu X; Liu J; Yang L
Cancer Immunol Immunother; 2019 Jan; 68(1):121-130. PubMed ID: 30306202
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Yokota C; Kagawa N; Takano K; Chiba Y; Kinoshita M; Kijima N; Oji Y; Oka Y; Sugiyama H; Tsuboi A; Izumoto S; Kishima H; Hashimoto N
Cancer Immunol Immunother; 2022 Jan; 71(1):189-201. PubMed ID: 34089373
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.
Higuchi Y; Koya T; Yuzawa M; Yamaoka N; Mizuno Y; Yoshizawa K; Hirabayashi K; Kobayashi T; Sano K; Shimodaira S
Biomedicines; 2015 Dec; 3(4):304-315. PubMed ID: 28536414
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
Jouanneau E; Poujol D; Gulia S; Le Mercier I; Blay JY; Belin MF; Puisieux I
Cancer Immunol Immunother; 2006 Mar; 55(3):254-67. PubMed ID: 16133115
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.
Kim CH; Hong MJ; Park SD; Kim CK; Park MY; Sohn HJ; Cho HI; Kim TG; Hong YK
Cancer Immunol Immunother; 2006 Nov; 55(11):1309-19. PubMed ID: 16463038
[TBL] [Abstract][Full Text] [Related]
8. Targeting of the WT1
Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.
Ogasawara M
Hum Vaccin Immunother; 2024 Dec; 20(1):2296735. PubMed ID: 38148629
[TBL] [Abstract][Full Text] [Related]
10. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.
Van Tendeloo VF; Van de Velde A; Van Driessche A; Cools N; Anguille S; Ladell K; Gostick E; Vermeulen K; Pieters K; Nijs G; Stein B; Smits EL; Schroyens WA; Gadisseur AP; Vrelust I; Jorens PG; Goossens H; de Vries IJ; Price DA; Oji Y; Oka Y; Sugiyama H; Berneman ZN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13824-9. PubMed ID: 20631300
[TBL] [Abstract][Full Text] [Related]
11. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors.
Lim DS; Kim JH; Lee DS; Yoon CH; Bae YS
Cancer Immunol Immunother; 2007 Nov; 56(11):1817-29. PubMed ID: 17443323
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial.
Märten A; Flieger D; Renoth S; Weineck S; Albers P; Compes M; Schöttker B; Ziske C; Engelhart S; Hanfland P; Krizek L; Faber C; von Ruecker A; Müller S; Sauerbruch T; Schmidt-Wolf IG
Cancer Immunol Immunother; 2002 Dec; 51(11-12):637-44. PubMed ID: 12439609
[TBL] [Abstract][Full Text] [Related]
13. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.
Tamir A; Basagila E; Kagahzian A; Jiao L; Jensen S; Nicholls J; Tate P; Stamp G; Farzaneh F; Harrison P; Stauss H; George AJ; Habib N; Lechler RI; Lombardi G
Cancer Immunol Immunother; 2007 Dec; 56(12):2003-16. PubMed ID: 17333181
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.
Bauer C; Dauer M; Saraj S; Schnurr M; Bauernfeind F; Sterzik A; Junkmann J; Jakl V; Kiefl R; Oduncu F; Emmerich B; Mayr D; Mussack T; Bruns C; Rüttinger D; Conrad C; Jauch KW; Endres S; Eigler A
Cancer Immunol Immunother; 2011 Aug; 60(8):1097-107. PubMed ID: 21547597
[TBL] [Abstract][Full Text] [Related]
16. Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.
Thompson EM; Landi D; Brown MC; Friedman HS; McLendon R; Herndon JE; Buckley E; Bolognesi DP; Lipp E; Schroeder K; Becher OJ; Friedman AH; McKay Z; Walter A; Threatt S; Jaggers D; Desjardins A; Gromeier M; Bigner DD; Ashley DM
Lancet Child Adolesc Health; 2023 Jul; 7(7):471-478. PubMed ID: 37004712
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell-based cancer immunotherapy targeting MUC-1.
Wierecky J; Mueller M; Brossart P
Cancer Immunol Immunother; 2006 Jan; 55(1):63-7. PubMed ID: 15864588
[TBL] [Abstract][Full Text] [Related]
18. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination.
De Vleeschouwer S; Ardon H; Van Calenbergh F; Sciot R; Wilms G; van Loon J; Goffin J; Van Gool S
Cancer Immunol Immunother; 2012 Nov; 61(11):2105-12. PubMed ID: 22565485
[TBL] [Abstract][Full Text] [Related]
19. Delayed-Type Hypersensitivity: An Excellent Indicator of Anti-tumor Immunity With Wilms' Tumor 1 (WT1) Dendritic Cell Vaccine Therapy.
Nagai H; Karube R
Cureus; 2023 Nov; 15(11):e49221. PubMed ID: 38143707
[TBL] [Abstract][Full Text] [Related]
20. Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.
Spira A; Hansen AR; Harb WA; Curtis KK; Koga-Yamakawa E; Origuchi M; Li Z; Ertik B; Shaib WL
Target Oncol; 2021 Jul; 16(4):461-469. PubMed ID: 33939067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
